Neurodegenerative diseases gene therapy (Apellis Pharmaceuticals)

N/A

Report date: 2025/01/26 16:22:31

Base Information

Drug NameNeurodegenerative diseases gene therapy (Apellis Pharmaceuticals)
Drug Alias Namegene therapy (C3/C3b secretor) (Apellis Pharmacueticals)
ClassificationBiologics
Mechanisms of ActionComplement C3 stimulants
TargetsComplement C3
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesApellis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNerve Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A